On Friday, CSX Corporation (NYSE:CSX)’s shares declined -3.60% to $28.13.
Building on its record of leading sustainability performance in the transportation sector, CSX was named to the Dow Jones Sustainability Index for North America for the fifth successive year.
CSX is the only U.S. railroad recognized by the Dow Jones Sustainability Index for North America and among just four transportation companies on the 2015 list. CSX showed strong performance across the assessed criteria, specifically in the areas of environmental policy and administration system, fuel efficiency, climate strategy, corporate governance, and stakeholder engagement.
The index is a partnership between the Dow Jones Indexes and RobecoSAM Sustainability Assessments, which tracks the financial performance of the world’s leading companies according to rigorous economic, environmental and social criteria.
CSX Corporation, together with its auxiliaries, provides rail-based transportation services in the United States and Canada. It offers traditional rail services, and transports intermodal containers and trailers. The company transports crushed stone, sand and gravel, metal, phosphate, fertilizer, food, consumer, agricultural, automotive, paper, and chemical products; and coal, coke, and iron ore to electricity-generating power plants, steel manufacturers, and industrial plants, in addition to exports coal to deep-water port facilities.
Netflix, Inc. (NASDAQ:NFLX)’s shares dropped -1.53% to $102.62.
Netflix, Inc. (NFLX) declared it will post its third-quarter 2015 financial results and business outlook on its investor relations website at http://ir.netflix.com on Wednesday, October 14, 2015, at about 1:05 p.m. Pacific Time. At that time the company will issue a brief advisory release via newswire containing a link to the third-quarter 2015 financial results and letter to shareholders on its website.
Netflix, Inc., an Internet television network, engages in the Internet delivery of TV shows and movies directly on TVs, computers, and mobile devices in the United States and internationally. The company operates in three segments: Domestic Streaming, International Streaming, and Domestic DVD.
At the end of Friday’s trade, Activision Blizzard, Inc. (NASDAQ:ATVI)‘s shares surged 0.42% to $31.10.
Bungie and Activision Publishing, Inc., a wholly owned partner of Activision Blizzard, Inc. (ATVI) have joined forces to bring the world Destiny: The Taken King, the epic follow-up to the blockbuster Destiny saga. Building upon Destiny, the biggest new video game franchise launch in history, Destiny: The Taken King expands the universe with a rich and diverse offering, counting new adventures, challenges, enemies, and weapons that make for the most ambitious addition to the Destiny universe yet. The Taken King can be purchased now, worldwide, in each territory where accessible at global retailers, and through console digital stores. Additionally, the ‘King’s Fall’ Raid will go live at 10 o’clock a.m. PDT on Friday, Sept. 18, giving millions of players in the Destiny community the biggest new challenge and commensurate rewards to date.
With a new storyline introducing Oryx, Crota’s vengeful father, an all-new destination, three new Guardian subclasses, a massive arsenal of new armor, weapons and exotics, new Strikes and Crucible maps, and the new ‘King’s Fall’ Raid that will put players to the ultimate test, there has never been a better time to jump in to “Become Legend,” particularly for new players starting their journey as a Guardian. The Taken King major expansion takes players deep into the chambers of a new destination, the ‘Dreadnaught’ ship, to defeat Oryx, and his Taken Army.
Activision Blizzard, Inc. develops and publishes online, personal computer (PC), video game console, handheld, mobile, and tablet games worldwide. The company develops and publishes interactive entertainment software products through retail channels or digital downloads; and downloadable content to a range of gamers.
Advaxis, Inc. (NASDAQ:ADXS), ended its Friday’s trading session with -4.72% loss, and closed at $18.78.
Advaxis, Inc. (ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and the Gynecologic Oncology Group (GOG, now part of NRG Oncology), today announced clinical data from Stage 1 of an ongoing two-stage Phase 2 study (GOG-0265) of Advaxis’s lead Lm Technology(TM) immunotherapy, axalimogene filolisbac (ADXS-HPV), in patients with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC) who have progressed on at least one prior line of systemic therapy. The Stage 1 data showed that treatment with axalimogene filolisbac resulted in a 38.5 percent 12-month overall survival rate in 26 patients.
Evaluation of safety data showed that Grade 1 or 2 adverse events occurred in 19 out of 26 patients (73 percent), with fatigue, chills and fever being the most common. Four patients (15 percent) experienced a Grade 3 adverse event (hypotension and cytokine release syndrome) and one patient (4 percent) experienced a Grade 4 adverse event (lung infection and sepsis). The results were presented at the American Gynecological & Obstetrical Society (AGOS) annual meeting in Half Moon Bay, Calif. by Tom Herzog, M.D., Clinical Director at the University of Cincinnati Cancer Institute.
Evaluation of safety data showed that Grade 1 or 2 adverse events occurred in 19 out of 26 patients (73 percent), with fatigue, chills and fever being the most common. Four patients (15 percent) practiced a Grade 3 adverse event (hypotension and cytokine release syndrome) and one patient (4 percent) practiced a Grade 4 adverse event (lung infection and sepsis). The results were presented at the American Gynecological & Obstetrical Society (AGOS) annual meeting in Half Moon Bay, Calif. by Tom Herzog, M.D., Clinical Director at the University of Cincinnati Cancer Institute.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
